[Genetic Diagnostics in Everyday Clinical Practice in Child and Adolescent Psychiatry: Indications, Framework Conditions, Hurdles, and Proposed Solutions].

Genetic Diagnostics in Everyday Clinical Practice in Child and Adolescent Psychiatry: Indications, Framework Conditions, Hurdles, and Proposed Solutions Abstract: Health insurance covers medically necessary genetic testing in Germany. Diagnostic genetic testing has become increasingly important for child and adolescent psychiatry (CAP), reflected by the rising number of national guidelines relevant to CAP, including genetic testing in the recommended diagnostic work-up. However, implementation of theses guidelines in routine clinical care is lacking. This article provides a concise overview of the relevance of genetic testing in CAP-related national guidelines. It outlines the legal and financial framework for genetic testing in Germany. Furthermore, it points out barriers to implementation and offers potential solutions. It then provides examples from clinical practice highlighting the potential benefits patients and their family members might have from receiving a genetic diagnosis. The article closes by outlining future CAP-relevant areas in which genetic testing may become clinically relevant.

[1]  L. Vissers,et al.  How to proceed after “negative” exome: A review on genetic diagnostics, limitations, challenges, and emerging new multiomics techniques , 2022, Journal of inherited metabolic disease.

[2]  M. Butler,et al.  Actionable Genomics in Clinical Practice: Paradigmatic Case Reports of Clinical and Therapeutic Strategies Based upon Genetic Testing , 2022, Genes.

[3]  D. Geschwind,et al.  Comparing Copy Number Variations in a Danish Case Cohort of Individuals With Psychiatric Disorders. , 2021, JAMA psychiatry.

[4]  D. Ledbetter,et al.  Medical manifestations and healthcare utilization among adult MyCode participants with neurodevelopmental psychiatric copy number variants , 2021, Genetics in Medicine.

[5]  T. Al-Saadi,et al.  Systemic review and meta-analysis of the intellectual integrity of children with Neurofibromatosis type 1 (NF-1). , 2021, World neurosurgery.

[6]  T. Scherer,et al.  Angeborene Adipositasformen und Therapien , 2021, Journal für Klinische Endokrinologie und Stoffwechsel.

[7]  J. Hebebrand,et al.  Need for psychiatric phenotyping in patients with rare genetic disorders , 2021, European Child & Adolescent Psychiatry.

[8]  D. Ledbetter,et al.  Diagnostic genetic testing for neurodevelopmental psychiatric disorders: closing the gap between recommendation and clinical implementation. , 2021, Current opinion in genetics & development.

[9]  N. Wray,et al.  Could Polygenic Risk Scores Be Useful in Psychiatry?: A Review. , 2020, JAMA psychiatry.

[10]  F. Quintero-Rivera,et al.  The Feasibility and Outcomes of Genetic Testing for Autism and Neurodevelopmental Disorders on an Inpatient Child and Adolescent Psychiatry Service , 2020, Autism research : official journal of the International Society for Autism Research.

[11]  D. Ledbetter,et al.  Long overdue: including adults with brain disorders in precision health initiatives. , 2020, Current opinion in genetics & development.

[12]  M. Owen,et al.  Increasing the Clinical Psychiatric Knowledge Base About Pathogenic Copy Number Variation. , 2020, The American journal of psychiatry.

[13]  J. Sebat,et al.  Identifying schizophrenia patients who carry pathogenic genetic copy number variants using standard clinical assessment: retrospective cohort study , 2020, The British Journal of Psychiatry.

[14]  Janice M. Fullerton,et al.  Polygenic risk scores in psychiatry: Will they be useful for clinicians? , 2019, F1000Research.

[15]  S. Scherer,et al.  Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disorders , 2019, Genetics in Medicine.

[16]  G. Kirov,et al.  Cognitive performance and functional outcomes of carriers of pathogenic copy number variants: analysis of the UK Biobank , 2019, The British Journal of Psychiatry.

[17]  P. Krawitz.  Klinisch-bioinformatische Analyse bei Intelligenzminderung , 2019, medizinische genetik.

[18]  L. Armengol,et al.  High Incidence of Copy Number Variants in Adults with Intellectual Disability and Co-morbid Psychiatric Disorders , 2018, Behavior genetics.

[19]  J. Vermeesch,et al.  Neurodevelopmental risk copy number variants in adults with intellectual disabilities and comorbid psychiatric disorders , 2018, British Journal of Psychiatry.

[20]  John Wei,et al.  Impact of IQ on the diagnostic yield of chromosomal microarray in a community sample of adults with schizophrenia , 2017, Genome Medicine.

[21]  Alecia C. Vogel,et al.  Neurodevelopmental disorders in children with neurofibromatosis type 1 , 2017, Developmental medicine and child neurology.

[22]  R. Jardri,et al.  An overview of medical risk factors for childhood psychosis: Implications for research and treatment , 2017, Schizophrenia Research.

[23]  Daniele Merico,et al.  Molecular Diagnostic Yield of Chromosomal Microarray Analysis and Whole-Exome Sequencing in Children With Autism Spectrum Disorder. , 2015, JAMA.

[24]  Daniele Merico,et al.  Pathogenic rare copy number variants in community-based schizophrenia suggest a potential role for clinical microarrays. , 2013, Human molecular genetics.

[25]  Robert Koch-Institut,et al.  Richtlinie der Gendiagnostik- Kommission (GEKO) über die Anforderungen an die Qualifikation zur und Inhalte der genetischen Beratung gemäß § 23 Abs. 2 Nr. 2a und § 23 Abs. 2 Nr. 3 GenDG , 2011 .

[26]  Leslie G Biesecker,et al.  Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. , 2010, American journal of human genetics.

[27]  Gerome Breen,et al.  Psychiatric Genomics: An Update and an Agenda , 2017, bioRxiv.